Demographic characteristics, rates of neutropenic fever, and chemotherapy dose reductions among patients treated for plasma cell disorders (N = 136) with DANC vs without DANC
| . | All patients . | Patients with DANC . | Patients without DANC . |
|---|---|---|---|
| Patients | 136 (100%) | 52/136 (38%) | 84/136 (62%) |
| Age, mean (SD) | 65 | 65 (±12) | 65 (±11) |
| Sex | |||
| Female | 62 (47%) | 26 (50%) | 36 (43%) |
| Self-identified race | |||
| Non-Hispanic Black | 74/136 (54%) | 48 (92%) | 26 (31%) |
| Non-Hispanic White | 34/136 (25%) | 0 (0%) | 34 (41%) |
| Hispanic | 18/136 (13%) | 2 (4%) | 16 (19%) |
| Other∗ | 10/136 (7%) | 2 (4%) | 8 (10%) |
| Malignancy | |||
| MM† | 94/136 (69%) | 46/52 (89%) | 48/84 (57%) |
| Stage I | 24/94 (28%) | 11/46 (24%) | 13/48 (27%) |
| Stage II | 41/94 (49%) | 19/46 (41%) | 22/48 (46%) |
| Stage III | 21/94 (27%) | 12/46 (26%) | 9/48 (19%) |
| Smoldering or missing | 8/94 (9%) | 4/46 (9%) | 4/48 (8%) |
| AL amyloidosis‡ | 34/136 (23%) | 2/52 (6%) | 32/84 (37%) |
| Stage I | 9/34 (26%) | 1/2 (50%) | 8/32 (25%) |
| Stage II | 9/34 (26%) | 1/2 (50%) | 8/32 (25%) |
| Stage IIIa | 8/34 (24%) | 0 (0%) | 8/32 (25%) |
| Stage IIIb | 8/34 (24%) | 0 (0%) | 8/32 (25%) |
| MM-associated AL amyloidosis | 5/136 (4%) | 1/52 (2%) | 4/52 (5%) |
| Other§ | 3/136 (2%) | 2/52 (4%) | 1/52 (1%) |
| Neutropenia|| | |||
| Baseline neutropenia | 25/129 (19%) | 17/50 (34%) | 8/79 (10%) |
| Neutropenia during treatment | 83/134 (62%) | 44/52 (85%) | 39/82 (48%) |
| With baseline neutropenia | 25/25 (100%) | 17/17 (100%) | 8/8 (100%) |
| Without baseline neutropenia | 58/104 (56%) | 25/33 (76%) | 29/71 (41%) |
| Febrile neutropenia | 7/136 (5%) | 0/52 (0.0%) | 7/84 (8%) |
| No. of lines¶ | |||
| 1 line | 45/136 (33%) | 13/52 (25%) | 32/84 (38%) |
| 2 lines | 35/136 (26%) | 8/52 (15%) | 27/84 (32%) |
| ≥3 lines | 56/136 (41%) | 31/52 (60%) | 25/84 (30%) |
| Received autologous SCT | |||
| MM | 25/136 (18%) | 13/52 (25%) | 12/84 (14%) |
| AL amyloidosis | 3/136 (2%) | 2/52 (4%) | 1/84 (1%) |
| Chemotherapy dose reduction | |||
| During treatment# | 95/136 (70%) | 37/52 (71%) | 58/84 (69%) |
| Antibiotics | |||
| Any | 111/136 (82%) | 45/52 (87%) | 66/84 (79%) |
| Oral levofloxacin | 64/111 (58%) | 27/45 (60%) | 37/66 (56%) |
| Oral, other | 94/111 (85%) | 38/45 (84%) | 56/66 (85%) |
| Parenteral antibiotics | 81/111 (73%) | 32/45 (71%) | 49 (74%) |
| IVIG supplementation | 4/136 (3%) | 2/52 (4%) | 2/84 (2%) |
| . | All patients . | Patients with DANC . | Patients without DANC . |
|---|---|---|---|
| Patients | 136 (100%) | 52/136 (38%) | 84/136 (62%) |
| Age, mean (SD) | 65 | 65 (±12) | 65 (±11) |
| Sex | |||
| Female | 62 (47%) | 26 (50%) | 36 (43%) |
| Self-identified race | |||
| Non-Hispanic Black | 74/136 (54%) | 48 (92%) | 26 (31%) |
| Non-Hispanic White | 34/136 (25%) | 0 (0%) | 34 (41%) |
| Hispanic | 18/136 (13%) | 2 (4%) | 16 (19%) |
| Other∗ | 10/136 (7%) | 2 (4%) | 8 (10%) |
| Malignancy | |||
| MM† | 94/136 (69%) | 46/52 (89%) | 48/84 (57%) |
| Stage I | 24/94 (28%) | 11/46 (24%) | 13/48 (27%) |
| Stage II | 41/94 (49%) | 19/46 (41%) | 22/48 (46%) |
| Stage III | 21/94 (27%) | 12/46 (26%) | 9/48 (19%) |
| Smoldering or missing | 8/94 (9%) | 4/46 (9%) | 4/48 (8%) |
| AL amyloidosis‡ | 34/136 (23%) | 2/52 (6%) | 32/84 (37%) |
| Stage I | 9/34 (26%) | 1/2 (50%) | 8/32 (25%) |
| Stage II | 9/34 (26%) | 1/2 (50%) | 8/32 (25%) |
| Stage IIIa | 8/34 (24%) | 0 (0%) | 8/32 (25%) |
| Stage IIIb | 8/34 (24%) | 0 (0%) | 8/32 (25%) |
| MM-associated AL amyloidosis | 5/136 (4%) | 1/52 (2%) | 4/52 (5%) |
| Other§ | 3/136 (2%) | 2/52 (4%) | 1/52 (1%) |
| Neutropenia|| | |||
| Baseline neutropenia | 25/129 (19%) | 17/50 (34%) | 8/79 (10%) |
| Neutropenia during treatment | 83/134 (62%) | 44/52 (85%) | 39/82 (48%) |
| With baseline neutropenia | 25/25 (100%) | 17/17 (100%) | 8/8 (100%) |
| Without baseline neutropenia | 58/104 (56%) | 25/33 (76%) | 29/71 (41%) |
| Febrile neutropenia | 7/136 (5%) | 0/52 (0.0%) | 7/84 (8%) |
| No. of lines¶ | |||
| 1 line | 45/136 (33%) | 13/52 (25%) | 32/84 (38%) |
| 2 lines | 35/136 (26%) | 8/52 (15%) | 27/84 (32%) |
| ≥3 lines | 56/136 (41%) | 31/52 (60%) | 25/84 (30%) |
| Received autologous SCT | |||
| MM | 25/136 (18%) | 13/52 (25%) | 12/84 (14%) |
| AL amyloidosis | 3/136 (2%) | 2/52 (4%) | 1/84 (1%) |
| Chemotherapy dose reduction | |||
| During treatment# | 95/136 (70%) | 37/52 (71%) | 58/84 (69%) |
| Antibiotics | |||
| Any | 111/136 (82%) | 45/52 (87%) | 66/84 (79%) |
| Oral levofloxacin | 64/111 (58%) | 27/45 (60%) | 37/66 (56%) |
| Oral, other | 94/111 (85%) | 38/45 (84%) | 56/66 (85%) |
| Parenteral antibiotics | 81/111 (73%) | 32/45 (71%) | 49 (74%) |
| IVIG supplementation | 4/136 (3%) | 2/52 (4%) | 2/84 (2%) |
All values reported as N (%) unless otherwise specified.
SD, standard deviation; with DANC, Fy (a−b−); without DANC, Fy (a−b+), Fy (a+b−), and Fy (a+b+).
Other races include Asian, Native Hawaiian/Pacific Islander, and “choose not to answer.”
MM Revised International Staging System stage unavailable for the patient (who had high-risk smoldering MM).
AL amyloidosis staging is based on the Mayo 2004 staging system and its European modifications.
Other malignancies include 2 patients with AL immunoglobulin deposition disease and 1 patient with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes syndrome.
Neutropenia: ANC <1800×109/L (lower limit of laboratory normal). Baseline neutropenia refers to neutropenia before the first chemotherapy (lenalidomide, pomalidomide, cyclophosphamide, carfilzomib, bortezomib, or melphalan). Missing data: some patients had an unknown baseline ANC due to prior treatment at another institution, and denominators included cases in which missing data were removed).
For patients with AL amyloidosis, autologous stem cell transplant was considered 1 line of treatment (not for MM).
Indicates the receipt of a dosage of chemotherapy lower than that originally ordered (due to any cause).